AU2019211491B2 - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof - Google Patents

2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof Download PDF

Info

Publication number
AU2019211491B2
AU2019211491B2 AU2019211491A AU2019211491A AU2019211491B2 AU 2019211491 B2 AU2019211491 B2 AU 2019211491B2 AU 2019211491 A AU2019211491 A AU 2019211491A AU 2019211491 A AU2019211491 A AU 2019211491A AU 2019211491 B2 AU2019211491 B2 AU 2019211491B2
Authority
AU
Australia
Prior art keywords
fluoro
methyl
pyridin
indazol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019211491A
Other languages
English (en)
Other versions
AU2019211491A1 (en
Inventor
Michael John COSTANZO
Michael Nicholas Greco
Jirong Peng
Don Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Pharma Inc
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of AU2019211491A1 publication Critical patent/AU2019211491A1/en
Application granted granted Critical
Publication of AU2019211491B2 publication Critical patent/AU2019211491B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019211491A 2018-01-29 2019-01-29 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof Active AU2019211491B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
US62/623,516 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
AU2019211491A1 AU2019211491A1 (en) 2020-07-30
AU2019211491B2 true AU2019211491B2 (en) 2024-03-14

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019211491A Active AU2019211491B2 (en) 2018-01-29 2019-01-29 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof

Country Status (15)

Country Link
US (1) US11352341B2 (https=)
EP (1) EP3746072B1 (https=)
JP (1) JP7337395B2 (https=)
KR (1) KR20200115583A (https=)
CN (1) CN111989099A (https=)
AU (1) AU2019211491B2 (https=)
BR (1) BR112020015405A2 (https=)
CA (1) CA3088381A1 (https=)
EA (1) EA202091450A1 (https=)
IL (1) IL275948A (https=)
MX (1) MX2020007959A (https=)
PH (1) PH12020551155A1 (https=)
SG (1) SG11202006748RA (https=)
TW (1) TW201940166A (https=)
WO (1) WO2019148161A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
MX2020013808A (es) * 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
MA55909A (fr) * 2019-05-05 2022-03-16 Qilu Regor Therapeutics Inc Inhibiteurs de cdk
US12570633B2 (en) 2020-06-22 2026-03-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Preparation method for CDK4/6 inhibitor
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
AU2004255934B2 (en) 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US9796701B2 (en) * 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
CN111333627B (zh) * 2015-03-11 2024-09-13 正大天晴药业集团股份有限公司 作为抗癌药物的取代的2-氢-吡唑衍生物
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof

Also Published As

Publication number Publication date
SG11202006748RA (en) 2020-08-28
US20210139459A1 (en) 2021-05-13
WO2019148161A1 (en) 2019-08-01
MX2020007959A (es) 2020-09-18
IL275948A (en) 2020-08-31
JP7337395B2 (ja) 2023-09-04
CA3088381A1 (en) 2019-08-01
JP2021512161A (ja) 2021-05-13
PH12020551155A1 (en) 2021-06-07
US11352341B2 (en) 2022-06-07
KR20200115583A (ko) 2020-10-07
TW201940166A (zh) 2019-10-16
AU2019211491A1 (en) 2020-07-30
EP3746072B1 (en) 2023-04-12
EP3746072A4 (en) 2021-06-02
CN111989099A (zh) 2020-11-24
BR112020015405A2 (pt) 2020-12-08
EP3746072A1 (en) 2020-12-09
EA202091450A1 (ru) 2021-01-14

Similar Documents

Publication Publication Date Title
AU2019211491B2 (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof
AU2015292425B2 (en) 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
CA3214040A1 (en) Inhibiting ubiquitin-specific protease 1 (usp1)
DK3009431T3 (en) 2- (2,4,5-SUBSTITUTED ANILIN) -PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USED FOR CANCER TREATMENT
KR20180134983A (ko) Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
AU2012328167A1 (en) New compounds
CA2693880A1 (en) Pyrimidine derivatives 934
CA2982862C (en) Preparation and use of kinase inhibitor
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
OA19873A (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof.
EP4724443A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
WO2026047509A1 (en) Substituted triazine compound derivatives and their pharmaceutical use
AU2015261672B2 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
HK40034278A (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
OA18720A (en) 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof.